The mechanism by which leukemic cells interfere with normal hematopoiesis remains unclear. We show here that, whereas the leukemic KG1a cells are naturally devoid from cellular cytotoxicity, once activated by TNFa, they display cytolytic activity toward various cellular targets including CFU-GM. This mechanism is dependent on stimulation of the granzyme B/ perforin system. In addition, KG1a cells expressed the NKG2D receptor and its signal-transducing adaptator DAP 10, which were functional as confirmed by redirected lysis experiments. Interestingly, flow cytometry analysis of 20 samples of patients with acute myeloid leukemia (AML) (FAB M0-M5) revealed the expression of NKG2D (40%) and other natural cytotoxicity receptors (40% for NKp30, 74% for NKp44, 39% for NKp46) by a pool 415% of leukemic cells. Furthermore, CD34
Introduction
Myelodysplasic syndromes (MDS) represent a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis and a variable risk of transformation to acute myeloid leukemia (AML). Pancytopenia of one or more myeloid lineage is a common feature observed, while leukemic contingent is restricted by definition to less than 20% of total bone marrow cells (WHO classification). Excessive apoptosis of hematopoietic progenitors (HPCs) has been shown to contribute to this ineffective hematopoiesis and chronic inflammation seems to be associated with the emergence of primary MDS in old patient. 1, 2 Among the proinflammatory cytokines, TNFa could be directly involved in inhibition of hematopoietic stem cell renewal and bone marrow progenitor clonogeny (CFU-Meg and CFU-E), but has little effect on granular/monocytic progenitors. 3 Whereas the origin of TNFa overproduction can be diverse (immune cells in Th1 response, bone marrow microenvironment and some leukemic clones), [4] [5] [6] malignant leukemic clones of the immature compartment are resistant to this cytokine. 7 Many reports describe aberrant lymphoid (T lymphocytes and natural killer (NK)) marker expressions in AML cells, such as CD7, CD56 and CD11a. [8] [9] [10] The existence of a possible common myeloid/NK precursor cell is also debated. 11 A case report shows that interleukin (IL)-2-stimulated CD33 þ CD56 þ CML cells exhibit an NK-like toxicity toward K562 target cells. 12 In this way, another case report shows that T-cell MDS-derived cell line could kill CD34 þ myeloid progenitors via the granzyme B (GrB)/Perforin (PFN) pathway, depending on CX3CR1/Fractalkine interaction. 13 In addition, we have previously demonstrated the expression of PFN and GrB in CD34 þ AML cells which can be upregulated and localized in cytotoxic granules upon genotoxic stress.
14 Finally, such CD34 þ AML stimulation induced a cytotoxic potential depending on the GrB/ PFN system toward myeloid or lymphoid target cells. Based on these results, we hypothesized that TNFa could also act indirectly in MDS and in AML, rendering malignant cells toxic toward normal hematopoietic cells, thus enhancing the normal myeloid cell depletion.
Nevertheless, interaction between effectors and target cells remains a crucial event in the cytotoxic process. In the context of the hypothetic NK-like toxicity of leukemic blasts, nothing is known about the status of activating NK receptors (NKR). 15 Such receptors trigger exocytosis of lytic granules in NK cells. 16, 17 While NKG2D is expressed in both lymphoid (NK, T lymphocytes CD4 þ CD8 þ , TCRa/b þ as well as TCRg/ d þ ) [17] [18] [19] and myeloid lineage, 20 natural cytotoxicity receptor (NCR) expression, such as NKp30, NKp44 and NKp46, seems to be NK restricted. The NKG2D ligands comprise MHC class I-related gene A and B (MICA and MICB) and the members of the cytomegalovirus UL16 binding proteins (ULBP1-4) family. 18, 21 MICA and MICB expression is generally weak or null at the surface of physiological cells, but they could be induced in cancer cells of epithelial origin upon different stresses.
22 NKG2D ligand expression on nontransformed cells has also been described. 19, 22 Signalling induced by NKG2D ligands is closely dependant on the transducing molecule DAP10. This association leads to p85 PI3K activation and subsequent cytotoxic granule exocytosis. 23 Otherwise, little is known about endogenous NCRs ligands, since NKp44 and NKp46 could recognize viral hemagglutinins while NKp30 and NKp46 might bind heparin sulfate proteoglycans. [24] [25] [26] [27] A recent study which developed NCR-soluble dimers reveals that NCR ligands are expressed on physiological CD34 þ cells undergoing granular/monocyte differentiation and are upregulated upon INF-g treatment. 28 Crosslinking of NCRs induces coupling of signal-transducing adaptator molecules DAP12 for NKp44, and CD3x, FceRIg for NKp30 and NKp46. 29 Altogether, these data allowed us to hypothesize that, in the context of inflammation of myeloid disorders, TNFa may activate the cytotoxic potential of AML cells against normal hematopoietic cells. The aim of the present study was to investigate this hypothesis and to define a potential role of GrB and NKR in this phenomenon.
Materials and methods

Cells
KG1a (promyeloblastic), HEL (erythromyeloblastic), K562 (CML, erythroblastic) and U937 (monoblastic) human leukemia cell lines were obtained from the ATCC (Rockville, MD, USA), NK92 cell line was kindly provided by Dr E Vivier (Marseille, France). Cells were maintained in IMDM medium with decomplemented 20% FCS (KG1a) and RPMI-1640 medium with 10% FCS for RPMI-1640 (HEL, K562, U937 and NK92). NK92 cell culture medium was supplemented with glycosylated recombinant human IL-2 (10 ng/ml corresponding to 200 IU/ml) kindly provided by Sanofi Synthelabo (Labège, France). All media were complemented with: 2 mM L-glutamine, 200 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Cergy Pontoise, France). All cells were maintained at 371C in a fully humidified 5% CO 2 incubator. Fresh leukemic cells, normal hematopoietic cells (CFU-GM) and CD34
þ HPCs were obtained from the Laboratoire d'Hématologie de Toulouse Purpan (Dr C DEMUR, Toulouse, France) from donors after informed consent. Cells were harvested from bone marrow by Ficoll-Hypaque density-gradient centrifugation. Fresh leukemic cells were maintained in RPMI-1640 10% FCS, supplemented with 10% supernatant of 5637 cell line. 30 Normal CD34 þ HPC purification and isolation from bone marrow mononuclear cells was performed by positive selection of CD34-expressing cells. Briefly, cells were magnetically labelled using MACS CD34 Microbeads (Miltenyi Biotec, Bergish Gladbach, Germany), and then isolated by positive selection through the MS separation column (Miltenyi Biotec, Bergish Gladbach, Germany). The purity of the CD34 cells was evaluated by flow cytometry using anti-CD45 and -CD34 monoclonal antibodies, and reached 85-98%. CD34
þ HPCs (1 Â 10
6
) were then cultivated in IMDM 10% BIT (bovine serum albumin, insulin, transferrin) with IL-3 (1 IU/ml), FLT3 ligand (10 ng/ml), stem cell factor (SCF) (100 ng/ml) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (10 ng/ml).
Drugs and reagents
Recombinant human TNFa, IL-3, GM-CSF, FLT3-L and SCF were purchased from Peprotech (Tebu, Le Perray en Yvelines, France). The following antibodies were used in Western blot analysis: anti-GrB (clone GrB-7) and anti-actin mAbs from Euromedex (Souffelweyersheim, France), anti-PFN mAb from Kamiya (Seattle, USA), anti-DAP10 and anti-DAP12 mAbs from Tebu (Le Perray en Yvelines, France). Isotypic controls IgG1 and IgG2a, anti-CD 11b, anti-CD13, anti-CD14, anti-CD15, anti-CD45 FITC-conjugated mAbs, anti-CD34, anti-CD38, anti-CD33, anti-NKG2D, anti-NKp30, anti-NKp44, anti-NKp46, secondary polyclonal goat anti-mouse IgG PEconjugated Ab, secondary rabbit anti-goat and goat anti-mouse HRP-conjugated, anti-CD11a and anti-CD58 mAbs were supplied from Beckman-Coulter (Roissy, France). Anti-NKG2D, anti-MICA (IgG2b clone 159227), anti-ULBP1 (IgG2a clone 170818), anti-ULBP2 (IgG2a clone 165903), anti-ULBP3 (IgG2a clone 166510) mAbs and mouse isotypic controls IgG1, IgG2a and IgG2b were purchased by R&D Systems Europe (Lille, France). FcR-blocking reagent was from Miltenyi Biotec (Bergish Gladbach, Germany). Trizol Reagent, Superscriptt kit onestep RT-PCR Superscriptt and First Strand Synthesis System for RT-PCR were supplied by Invitrogen (Cergy-Pontoise, France). Other products were purchased from Sigma (Saint QuentinFallavier, France).
Cytotoxicity assays
The CytoTox 96
s Non-Radioactive Cytotoxicity Assay (Promega, Charbonnières-les-bains, France) was used to evaluate AML cell cytotoxicity. This system is a colorimetric assay analogous to 51 Cr release radioactive assay. 31 For the direct cytototoxic assays, effector cells (KG1a, HEL, 8 Â 10 6 or 4 Â 10 6 cells/ml) were pretreated for 72 h with TNFa (20 ng/ml), washed, then resuspended in RPMI-1640 supplemented with 5% FCS and mixed with target cells (K562, U937: 1 Â 10 5 cells/ml) in U-bottom 96-microwell plates (Nunc, Roskilde, Denmark) at various E:T ratios in triplicates. Microplates were spun for 3 min at 300 g and incubated for 4 h at 371C, 5% CO 2 . Results were obtained according to the manufacturer's protocol. Maximum release (TM) was determined by lysing target cells with 20 ml of Lysis Solution s . Spontaneous release (TS) was determined by incubation of target cells in medium in the absence of effector cells. Effector spontaneous release (ES) was carried out with effector cells alone at the same E:T ratio. Results are expressed as percentage of cytotoxicity using the following formula: % Cytotoxicity ¼ ((ExperimentalÀESÀTS)/ (TMÀTS)) Â 100. Blocking experiments were performed with DCIC (50 mM), a broadly reactive serine esterase inhibitor, which has been shown to neutralize granzyme enzymatic activity, and MgCl 2 /EGTA (1.5 mM/1 mM), which blocks exocytosis and prevents PFN polymerization. 32, 33 In redirected lysis experiments, 1 Â 10 6 of murine P815 cells were first incubated with anti-NKG2D (2.5 mg) or IgG1 isotypic control for 1 h, washed twice and resuspended in RPMI-1640 at 1 Â 10 5 cells/ml. Then, these cells are used as targets in the cytotoxic assay. In addition, LDH release experiments were confirmed by 51 Cr release assay. Briefly, K562 cells were labelled with 200 mCi of 51 Cr (sodium chromate, MP Biomedicals) for 1 h at 371C, and washed three times. 51 Cr-labelled target cells (10 4 ) were added to effector cells at the indicated E:T ratio, in triplicates. Spontaneous release and total release were measured in wells receiving no effector cells and medium or 1 M HCl, respectively. After incubation for 4 h at 371C, 50 ml of supernatant collected and the released 51 Cr was measured in a Perkin-Elmer gamma counter. Percentage of specific lysis was calculated as follows: % of specific lysis ¼ ((sample releaseÀspontaneous release)/total releaseÀspontaneous release)) Â 100.
Clonogenic assay
Cytotoxicity against myeloid progenitors was analyzed after coculture in methylcellulose. Briefly, KG1a cells were treated or not by TNFa (20 ng/ml) during 72 h. KG1a-treated cells were then cocultivated during 4 h with normal marrow cells (from healthy donors). After sowing on methylcellulose in the presence of growth factors (10% supernatant of 5637 cell line) during 14 days (371C, 5% CO 2 ), cytotoxicity was evaluated by enumeration of the CFU-GM clones. This approach was possible because KG1a cells do not form colonies in this semi-solid medium.
Western blot analysis
For KG1a and HEL, cells were washed with ice-cold PBS, harvested, resuspended in RIPA lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40 (NP-40), 1% Triton X-100, 5 mM EDTA, 1 mM DTT, 1 mM Na 3 VO 4 , 10mM b-glycerophosphate, 2 mg/ml leupeptin, 2 mg/ml pepstatin, TNFa stimulates lytic activity of AML cells F Guilloton et al 10 mg/ml aprotinin, 50 mM NaF, 0.1 mM PMSF), incubated (30 min, 41C) and then centrifuged (13 000 g, 5 min, 41C).
Cell extracts (40 mg) or patient cells (2 Â 10 5 cells/10 ml) were boiled in Laemmli buffer containing 4% b-mercaptoethanol, separated on SDS-PAGE, and transferred electrophoretically onto nitrocellulose membranes (Hybondt-C extra, Amersham Life Science, Cergy-Pontoise, France). Nonspecific binding sites were blocked in PBS containing 0.1% Tween-20, 2% nonfat milk (for GrB and PFN) or 10% nonfat milk (for others proteins). Membranes were incubated overnight at 41C with the suitable antibodies. Membranes were then washed five times at room temperature, and bound Ig was detected with the appropriated secondary polyclonal antibodies coupled to HRP. The signal was visualized by enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, UK) and autoradiography.
Total RNA extraction
Total RNA was isolated by Trizol Reagent according to the manufacturer's protocol and resuspended in DEPC-treated water. RNA quantification, purity and integrity were determined by spectrophotometry (A260, A280 and A320) and 1.5% agarose gel electrophoresis.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
The RT-PCR multiplex reaction was carried out by Superscriptt kit one-step RT-PCR with PLATINUM s Taq according to the manufacturer's recommendations, on 0.2 mg of total RNA with the following cycles: reverse transcription at 501C for 30 min, amplification at 941C for 5 min, then 30 cycles at 941C for 1 min, 601C for 1 min, 721C for 1 min and a final elongation at 721C for 10 min. PCR amplification was carried out using the following primer pairs: GrB fwd: 5 0 -TGCGGAAGATCGAAAGT GCG-3 0 , GrB rev:
0 . Primer concentrations were 2 mM for GrB and 0.1 mM for b-actin. Distilled DEPC water was used as negative control. RT-PCR products were analyzed after electrophoresis in a 2% agarose gel stained with 0.5 mg/ml ethidium bromide, and visualized by UV light.
cDNA synthesis and quantitative PCR cDNAs were made using the Superscriptt First Strand Synthesis System for RT-PCR according to the manufacturer's recommendations on 2 mg of total RNA with 0.25 mg oligo(dT) [12] [13] [14] [15] [16] [17] [18] and 25 ng random hexamer with 50 U of Superscriptt II RT. Quantitative PCR was performed on an ABI7000 (Applied Biosystems, Courtaboeuf, France) using SYBR green PCR reagents in a 25 ml reaction mixture on 5 ml of a 1/40e cDNA dilution (SYBR Green Jumpstart Taq Ready Mix, Sigma, France). Amplification consisted of 40 cycles at 951C for 30 s, and 601C for 1 min after initial incubation at 951C for 10 min. rGrB fwd 5 0 -TTCGTGCTGACAGCTGCTCACT-3 0 , rGrB rev 5 0 -CTCTCCA GCTGCAGTAGCATGA-3 0 and rb-actin fwd 5 0 -TCCCTGGAGA AGAGCTACGA-3 0 , rb-actin rev 5 0 -AGGAAGGAAGGCTGGAA GAG-3 0 , primers were used at a final concentration of 300 nM. PCR efficiencies determined for these primers PCR were, respectively, 89.5 and 89.1%, allowing us to use the DDC t method for absolute quantification. 32 PCR product specificity was evaluated by generating a dissociation curve following the manufacturer's recommendation.
Flow cytometry analysis
1 Â 10 5 cells were washed three times in PBS 1% FCS and incubated with the appropriate antibody in PBS 1% FCS. Then, primary mAb-incubated cells were stained by PE-conjugated secondary antidody and analyzed by flow cytometry (Facscan, Becton-Dickinson Co., San Jose, CA, USA). For HPCs staining, FcR-blocking reagent (1/10) was added at the first incubation.
Statistics
Quantitative experiments were analyzed using Student's t-test. All P-values resulted from the use of two-sided tests.
Results
Influence of TNFa on cytotoxic potential of AML cells
The influence of TNFa on AML cell line cytotoxicity was first evaluated using K562 and U937 myeloid cell lines as target cells. KG1a or HEL cells were treated with TNFa (20 ng/ml) for 72 h, washed, then incubated in the presence of target cells at various E:T ratios. Whereas untreated KG1a (Figure 1a) or HEL (Figure 1c ) cells displayed low cytotoxicity, TNFa activated cells exhibited potent cellular cytotoxicity against both K562 cells (Figure 1a , c) and U937 cells (data not shown), as measured by LDH release assay. This result has been confirmed using cytotoxic assay based on 51 Cr release (Figure 1b) . In parallel, we evaluated the influence of TNFa on KG1a cell cytotoxicity towards normal granulomonocytic progenitors (CFU-GM). KG1a cells were treated with TNFa (20 ng/ml) for 72 h, washed, incubated in the presence of bone marrow mononuclear cells at various E:T ratios, and then the coculture was seeded in methylcellulose. CFU-GM colonies were scored after 14 days culture in semisolid medium. Identification of CFU-GM colonies was facilitated by the lack of KG1a cell clonogenic capacity. As shown in Figure 1d , TNFa-treated KG1a cells displayed a potent cytotoxic activity against CFU-GM with near than 60% reduction of colony formation at E:T ratio as low as 20:1, whereas untreated KG1a cells induced only 15% CFU-GM reduction.
Finally, we investigated the role of GrB/PFN system in cytotoxic function of TNFa-treated KG1a cells. At first, when TNFa-activated KG1a cells were cocultured with K562 cells in the presence of either anti-TNFa-or anti-Fas-blocking antibodies, KG1a cell cytotoxicy was maintained, suggesting that neither soluble nor membrane-bound forms of TNFa or Fas ligand (Fas-L) were involved in KG1a lytic function (data not shown). This result was in fact expected, based on the welldocumented resistance of K562 cells to both TNFa and Fas-L. 33, 34 Interestingly, TNFa-treated KG1a cells exhibited no cytotoxicity against untreated KG1a cells, even at high E:T ratio, suggesting that KG1a cells were intrinsically resistant to their own lytic system (data not shown). Lytic function of TNFatreated KG1a cells was abolished when cells were pretreated either with 3,4-dichloroisocoumarin (DCIC) (50 mM for 1 h), an inhibitor GrB protease activity, 35, 36 or with MgCl 2 /EGTA (1.5 mM/1 mM for 1 h), which prevents PFN polymerization (Figure 1e) .
Altogether, these results showed that, upon activation with TNFa, myeloid leukemic cell lines acquired a potent cellular toxicity against myeloid cells of various origins, including normal myeloid progenitors, depending on the GrB/ PFN system.
Influence of TNFa on GrB and PFN expression in AML cells
As previously documented, Western blot analysis revealed that both GrB and PFN were constitutively expressed in the nucleus of KG1a and HEL cells.
14 However, treatment with TNFa resulted in a time-dependent increase of GrB expression in both cytoplasm and nucleus, which was detectable at 48 h and maximal at 72 h in both KG1a and HEL cell lines (Figure 2a) . Semiquantitative PCR showed that TNFa induced a timedependent increase of the GrB transcript (Figure 2b) , with a maximum at 48 h. At this time, we observed a 3-fold increase of GrB transcript quantified by real-time PCR (Figure 2c ). Importantly, TNFa did not influence PFN protein expression (Figure 2a ) as well as mRNA transcript (data not shown) either in KG1a cells nor in HEL cells.
In further studies, GrB and PFN expression level was investigated in 12 bone marrow AML samples (490% blasts, o1% CD56 þ , o2% CD3 þ ) and compared to KG1a levels. In all, 7/12 had comparable or greater GrB mRNA level with KG1a and all AML cells expressed PFN (data not shown). Treatment of All these data suggested that, in AML cell lines as well as in some fresh AML samples, TNFa induced GrB expression.
NKG2D receptor expression and function in KG1a cells
Since the cytotoxic activity of TNFa-treated KG1a seemed to be related to that of NK cells, we investigated the presence of one or more NKR implicated in target cell recognition and lysis. NK cells are known to express NKG2D, NCR (NKp30, NKp44 and NKp46) and adhesion molecules. At first, flow cytometry analysis revealed that KG1a express some adhesion molecules such as CD11a and CD58; this expression did not change under TNFa treatment (data not shown). However, neither NCR nor its adaptator DAP12 was detected in KG1a cell line (data not shown). Interestingly, KG1a cells expressed the NKG2D activating receptor (Figure 3a) . As NKG2D receptor needs an association with its coreceptor DAP10 to activate polarization and exocytosis of cytotoxic granules, we determined the DAP10 content of KG1a cells by Western blot analysis. KG1a express DAP10 at comparable levels than positive controls: U937 and NK92 cell lines (Figure 3b) . We detected the two glycosylated forms (top arrows) and the native DAP10 form in KG1a cell line. As shown in Figure 3a and b, treatment of KG1a cells by TNFa did not influence the expression of NKG2D and DAP10. Finally, the functionality of the NKG2D receptor in TNFa-activated KG1a cell was studied by redirected lysis experiments. Briefly, high-affinity FcgRI þ murin P815 cells were incubated with anti-NKG2D or isotypic control and used as target cells in cytotoxic assay. As shown in Figure 3c , only TNFa-treated KG1a cells were able to kill NKG2D-coated P815 target cells. These results (c) The functionality of NKG2D receptor was investigated by redirected lysis experiments toward murine P815 cells. KG1a cells, TNFastimulated (circles) or not (squares) were incubated (4 h, 371C) with anti-NKG2D (full) or isotypic control (empty) coated P815 cells at various E:T ratios. The cytotoxic activity (%) was determined by the LDH release following the formula described in Materials and methods. Results are the mean7s.d. of six independent experiments performed in triplicate. *Po0.02 compared to untreated cells.
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suggested that NKG2D/DAP10 expression and GrB induction were necessary to the cytotoxic potential of KG1a cells.
NKG2D and NCR expression in fresh myeloid leukemic cells
NKG2D as well as NCR expression was evaluated by flow cytometry on fresh AML samples. As shown in Table 1 , no correlation was found between NKR and CD34 expressions. Nevertheless, we observed that some fresh AML samples expressed NKR, suggesting that, in case of stress, these cells could acquire an NK-like cytotoxic activity, potentially directed against physiological bone marrow cells.
NKG2D ligand expression on hematopoietic progenitors
Since TNFa-stimulated KG1a cells killed CFU-GM and since the KG1a cell line as well as some AML samples expressed NKR, we evaluated by flow cytometry NKG2D ligand expression on hematopoietic precursors during granulomonocytic differentiation. We determined the status of NKG2D ligands in purified CD34 þ HPCs undergoing granular monocyte differentiation. Purified HPCs, CD34 bright , CD38 bright and CD33 bright (480%) did not display significant NKG2D ligand expression. Moreover, we found a significant increase of ULBP-2-and ULBP-3-positive cells concomitant with the emergence of
þ and CD11b þ markers, corresponding to the GM-CFU/G-CFU differentiation state. Interestingly, ULBP-2 expression was maintained after 7-day culture, whereas ULBP-3 expression decreased at this time ( Figure 4 ). All these results confirmed that CFU-GM cells could be considered as targets towards stressed AML cells. 43 and ovarian follicular cells. 44 Our results show that TNFa-treated AML cell lines killed CFU-GM as well as NK-sensitive K562 target cells. It is well described that the K562 cell line does not express CD95 receptor and is TNFa stimulates lytic activity of AML cells F Guilloton et al resistant to TNFa-induced apoptosis but highly sensitive to the PFN/GrB system. As inhibitors of PFN/GrB death pathway blocked cytotoxicity, we determined the cellular content of these proteins in AML cells after TNFa exposure. As previously described, GrB is only present in the nucleus of unstimulated KG1a cells. 14 Upon genotoxic stress, GrB was induced both at nuclear and cytoplasmic levels, and present with PFN in cytotoxic granules.
14 Interestingly, similar results were obtained after TNFa stimulation of KG1a cells. Indeed, GrB upregulation was found at both mRNA and protein levels, but no effect was observed on PFN expression. Moreover, GrB was induced either at the nuclear or cytoplasmic level, this latter localization being critical for inducing cytotoxicity. Furthermore, we observed GrB protein expression in a significant number of AML patient cells, and sometimes a GrB upregulation upon TNFa treatment.
All these observations may have important clinical implications in the setting of myeloid malignant disorders, including AML and MDS. Indeed, the presence of TNFa mRNA transcripts in AML cells have been largely documented, [45] [46] [47] whereas MDS is often associated with an overproduction of TNFa by bone marrow microenvironment or myeloid cells. 5, 6 Furthermore, activated T cells or monocytes can also contribute to TNFa overproduction, particularly in the context of severe sepsis, a common complication of these diseases. 48 Previous studies have established that TNFa may alter physiologic hematopoiesis by inhibiting bone marrow progenitors and hematopoietic stem cell renewal through a direct mechanism. 49, 50 However, based on our study, it is also conceivable that, in AML or in MDS, TNFa may also act indirectly by rendering malignant cells cytotoxic toward residual normal hematopoietic cells, and that this mechanism may at least contribute to hematopoiesis insufficiency.
The fact that TNFa-treated KG1a cells resist their own lytic capacity is an intriguing observation. Several mechanisms may account for KG1a resistance, including abnormal GrB receptor mannose 6-phosphate/insulin-like growth factor II receptor, 51 altered intracellular GrB-mediated cell lysis pathway or, as previously described in AML cells, impaired binding of PFN. 52 Among resistance mechanisms, we found that KG1a express the GrB inhibitor serine-protease inhibitor 9 (data not shown). 53, 54 Beyond the scope of our study, this result suggests that some AML cells exhibit an efficient protective mechanism against the GrB/PFN system, which may have serious implications in cell therapy with either autologous or allogeneic cellular immune effectors.
As cellular cytotoxicity of activated KG1a cells requires cell contact, the mechanism by which KG1a cells as well AML cells could interact with their target was in part investigated.
The hypothetic common NK/myeloid lineage led us to investigate the expression of activating receptors. First, we found that KG1a express adhesion molecules such as CD11a and CD58, 9 known to be implicated in immune synapse. Interestingly, CD11a has been directly implicated in granule exocytosis in NK cells 55 and large number of AML cells express CD11a. 9 Secondly, despite no NCR being detected on KG1a cells, the NKG2D-activating receptor was expressed. Moreover, DAP 10, its only signal transducer described so far in human, was expressed and the functionality of NKG2D was confirmed by redirected lysis experiments. NKG2D was also expressed by significant pools of AML cells (9/20) and predominantly in M2 and M4 AML (4/6 and 4/7). Then, the determination of expression of one or more NCR in AML cell samples showed that NKp30 (12/20), NKp44 (14/19) and NKp46 (7/18) were frequently expressed by AML cells. Interestingly, 14/19 AML cell samples (all M1 and M4) tested expressed NKp44. So far, its expression was described to be NK specific, but the NKp44 gene is known to be localized within the TREM cluster on human 6p21.1 chromosome, while TREM-1 and -2 are myeloid specific. 56 In these settings, it was of primary importance to determine expression of the NKG2D ligands on normal myeloid cells. 57 Our results show a significant increase of ULBP-2 and -3 during granular/monocyte differentiation of CD34 þ haematopoietic progenitors. These results seem to be in disagreement with those recently published by Nowbakht et al, 28 showing an ULBP1 expression during differentiation of HPC. This discrepancy could be explained by the fact that differentiation culture medium was not supplemented by IL-3 in their experiments. Nevertheless, hematopoietic progenitors and precursors of the granulomonocyte lineage express NKG2D and NCR ligands. This result reinforced the hypothesis of a negative interaction in between leukemic and physiologic hematopoiesis in AML or MDS. In conclusion, our data show that TNFa induced cytotoxic potential in AML cells, mediated by GrB, and directed against myeloid cells including CFU-GM. Nevertheless, further studies are needed to investigate whether this model of cellular interaction may occur in AML or MDS marrow. If this is the case, the GrB/PFN system might thus appear as an important mediator of the negative interaction existing between leukemic and physiologic hematopoiesis. TNFa stimulates lytic activity of AML cells F Guilloton et al de l'Education Nationale, de l'Enseignement Supérieur, et de la Recherche (MENESR).
